We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Mutation That Causes Growth-Hormone Deficiency Prevents Cancer and Diabetes

By LabMedica International staff writers
Posted on 10 Mar 2011
A mutation causing abnormally low growth-hormone activity appears to be responsible for eliminating diabetes and cancer in an isolated community located on the slopes of the Andes Mountains of Ecuador.

A study published in the February 16, 2011, issue of the journal Science Translational Medicine reported results obtained by observing the population of growth hormone-deficient individuals for more than 22 years. More...
During this period, health profiles of 100 individuals with Laron syndrome – caused by deficiency in a gene that prevents the body from using growth hormone - and 1,600 relatives of normal stature were monitored.

The results revealed that during 22 years of observation no cases of diabetes and only one nonlethal case of cancer were found in the Laron syndrome subjects. In comparison, among normal sized relatives living in the same towns during the same period, 5% were diagnosed with diabetes and 17% with cancer. Reduced insulin concentrations and a very low HOMA-IR (homeostatic model assessment–insulin resistance) index in Loran syndrome, indicating higher insulin sensitivity, could explain the absence of diabetes in these subjects.

Serum from Loran syndrome subjects reduced DNA breaks but increased apoptosis in cultures of human mammary epithelial cells treated with hydrogen peroxide. Furthermore, serum from these subjects also caused changes that promoted cellular protection and life-span extension in model organisms.

"The growth hormone receptor-deficient people do not get two of the major diseases of aging. They also have a very low incidence of stroke, but the number of deaths from stroke is too small to determine whether it is significant,” said senior author Dr. Valter Longo, professor of cellular and molecular biology at the University of Southern California (Los Angeles, USA). "Although all the growth hormone deficient subjects we met appear to be relatively happy and normal and are known to have normal cognitive function, there are a lot of strange causes of death, including many that are alcohol related.”

Related Links:

University of Southern California





Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
COVID-19 Antigen Self-Test
Panbio COVID-19 Antigen Self-Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.